Login
$IMNM
$17.69 +$0.08 (0.45%) After hours

$IMNM SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
09 Nov 2026 S-3ASR
09 Nov 2026 S-3ASR
09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition

Varegacestat PDUFA target action date of April 28, 2027; Marketing Authorization Application (MAA) validated by the European Medicines Agency (EMA)

30 Oct 2026 SCHEDULE 13G
05 Oct 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities

THIS STOCK ISSUANCE AGREEMENT (“Agreement”) is entered into as of October 2, 2026, by and between Bristol-Myers Squibb Company, a Delaware corporation having offices at Route 206 and Province Line Road, Princeton, New Jersey 08543 (“BMS”...

15 Sep 2026 Form 4: Higgins Jack, Chief Scientific Officer

Received 18,000 shares by exercise or conversion ($24.3K) · Sold 13,200 shares ($334K) · Gave 8,800 shares as a gift · 1 more

11 Sep 2026 144
14 Aug 2026 SCHEDULE 13G/A
14 Aug 2026 SCHEDULE 13G/A
12 Aug 2026 Form 4: Barchas Isaac, Director

Sold 10,125 shares ($264K) · Sold 62,291 shares ($1.63M) · Sold 11,048 shares ($301K)

12 Aug 2026 144
11 Aug 2026 S-8
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors

10 Aug 2026 Form 4: Barchas Isaac, Director

Sold 20,840 shares ($543K) · Sold 15,248 shares ($397K)

06 Aug 2026 Form 4: Horn Kinney, CHIEF BUSINESS OFFICER

Received 90,616 shares by exercise or conversion ($1.08M) · Sold 90,616 shares ($2.27M)

06 Aug 2026 144
04 Aug 2026 144

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support